A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05919095 |
Recruitment Status :
Not yet recruiting
First Posted : June 26, 2023
Last Update Posted : June 26, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Unresectable Gallbladder Cancer | Drug: Carrilizumab plus GEMOX | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 37 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer |
Estimated Study Start Date : | June 30, 2023 |
Estimated Primary Completion Date : | June 30, 2025 |
Estimated Study Completion Date : | June 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Carrilizumab plus GEMOX
Carrilizumab combinated With gemcitabine and oxaliplatin (GEMOX)
|
Drug: Carrilizumab plus GEMOX
PD-1 antibody,200mg,D1,intravenous infusion, the administration time is 60 (+15) minutes. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1,D8;oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment. |
- Radical resection rate [ Time Frame: 6 months ]The proportion of patients whose tumors converted to a surgically resectable state and achieved radical resection within 8 courses of medication in all patients enrolled.
- Objective response rate (ORR) [ Time Frame: 6 months ]Complete response (CR) and partial response (PR), at 6 months by RECIST v.1.1
- Disease control rate(DCR) [ Time Frame: 6 months ]Complete response (CR) ,partial response (PR) and stable disease, SD, at 6 months by RECIST v.1.1
- Progression-free survival (PFS) [ Time Frame: 6 months ]The time from first drug administration to the first documented disease progression according to RECIST version 1.1 or to death from any cause, whichever occurred first.
- Overall survival(OS) [ Time Frame: 6 months ]The time from first drug administration to death from any cause.
- The incidence of treatment-related adverse event [ Time Frame: 6 months ]Percentage of participants who experienced treatment-related adverse event
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The patient must sign an informed consent form;
- Age 18-75 years old, both male and female;
- ECOG performance status score (PS score) 0 or 1 point;
- Child-Pugh score A period;
- Patients with advanced or recurrent metastatic gallbladder cancer who are not suitable for radical surgery (R0), or non-radical surgery (R1), or palliative surgery, as confirmed by pathological histology or cytology.
- Have not received any systemic treatment within 6 months;
- The functional indicators of important organs meet the following requirements (1)Neutrophils≥1.5*109/L; platelets≥100*109/L; hemoglobin≥9g/dl; serum albumin≥3g/dl; (2)Thyroid-stimulating hormone (TSH) ≤ 2 times the upper limit of normal, and T3 and T4 are in the normal range; (3)Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; (4)Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 60ml/min (calculated by Cockcroft-Gault formula);
- The subject has at least 1 measurable lesion (according to RECIST1.1);
- For women who are not breastfeeding or pregnant, use contraception during treatment or 12 months after the end of treatment.
Exclusion Criteria:
- Past or simultaneous suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary carcinoma;
- Have used gemcitabine-based chemotherapy or have used PD-1 monoclonal antibody or PD-L1 monoclonal antibody treatment within 6 months;
- Severe cardiopulmonary and renal dysfunction;
- Hypertension that is difficult to control with drugs (systolic blood pressure (BP) ≥140 mmHg and/or diastolic blood pressure ≥90mmHg) (based on the average of ≥3 BP readings obtained by ≥2 measurements);
- Abnormal coagulation function (PT>14s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy;
- After antiviral treatment, HBV DNA>2000 copies/ml, HCV RNA>1000;
- A history of esophageal and gastric varices, significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;
- Active infections requiring systemic treatment; patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, and no formal anti-tuberculosis treatment or tuberculosis Still in the active period;
- Human immunodeficiency virus (HIV, HIV1/2 antibody) positive;
- A history of psychotropic drug abuse, alcohol or drug abuse;
- Known to have a history of severe allergies to any monoclonal antibodies, platinum drugs, or gemcitabine;
- Other factors judged by the investigator may affect the safety of the subjects or the compliance of the trial. Such as serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05919095
Contact: Rui Zhang, PhD | 020-34078840 | zhangr95@mail.sysu.edu.cn | |
Contact: Yanfang Ye | 020-81336505 | yeyfang@mail.sysu.edu.cn |
China, Guangdong | |
Sun Yat-sen Memorial Hospital, Sun Yat-sen University | |
Guangzhou, Guangdong, China, 376032 |
Principal Investigator: | Rui Zhang, PhD | Department of Biliary and Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
Responsible Party: | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
ClinicalTrials.gov Identifier: | NCT05919095 |
Other Study ID Numbers: |
SYSKY-2022-516-02 |
First Posted: | June 26, 2023 Key Record Dates |
Last Update Posted: | June 26, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
PD-1;GEMOX;Unresectable gallbladder cancer. |
Gallbladder Neoplasms Biliary Tract Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Biliary Tract Diseases Digestive System Diseases Gallbladder Diseases |